Page last updated: 2024-12-05

3-hydroxyaspartic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxyaspartic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-hydroxyaspartic acid : A hydroxy-amino acid that is aspartic acid in which one of the methylene hydrogens has been replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5425
CHEMBL ID3039080
CHEBI ID83981
SCHEMBL ID336363
MeSH IDM0057444

Synonyms (78)

Synonym
nsc-119128
nsc119128
nsc-119129
erythro-.beta.-hydroxy-dl-aspartic acid
aspartic acid, dl-erythro-
nsc119129
dl-erythro-.beta.-hydroxyaspartic acid
dl-aspartic acid, erythro-
nsc139979
erythro-3-hydroxy-dl-aspartate
.beta.-erythro-hydroxy-dl-aspartate
dl-threo-.beta.-hydroxyaspartic acid
NSC618260 ,
nsc-618260
2-amino-3-hydroxy-butanedioic acid
3-hydroxyaspartic acid
SDCCGMLS-0066971.P001
SPECTRUM4_001967
SPECTRUM_001134
SPECTRUM5_000765
malic acid, 3-amino-
1860-87-3
nsc-84663
aspartic acid, 3-hydroxy-
nsc84663
BSPBIO_002585
nsc158204
nsc-158204
nsc158205
NCGC00095968-01
KBIOSS_001614
KBIO2_001614
KBIO2_004182
KBIO2_006750
KBIO3_002085
KBIOGR_002438
SPECTRUM2_001914
SPECTRUM3_001123
SPBIO_001908
SPECTRUM501000
FT-0690419
FT-0692188
2-amino-3-hydroxysuccinic acid
71653-06-0
H0947
2-amino-3-hydroxybutanedioic acid
A826077
2-azanyl-3-oxidanyl-butanedioic acid
CCG-38483
NCGC00015504-02
nsc 84663
99a78v5yx2 ,
einecs 275-771-1
unii-99a78v5yx2
beta-hydroxy-dl-aspartic acid
threo-beta-hydroxyaspartate
dl-threo-3-hydroxyaspartic acid
FT-0625518
3-hydroxy-aspartic acid
chebi:83981 ,
CHEMBL3039080
d,l-threo-3-hydroxyaspartic acid
SCHEMBL336363
AKOS022145819
3-aminomalic acid
mfcd00128126
d -(+)-threo -beta-hydroxyaspartic acid
2-amino-3-hydroxy-succinic acid
DTXSID20875575
Q27157362
(2r,3r)-2-amino-3-hydroxy-succinicacid
CS-0206811
nsc 139979;threo-beta-hydroxy-l-aspartic acid
4-trans-propylcyclohexyl-4-propylbiphenyl
D90978
WCA65306
dl-aspartic acid, 3-hydroxy-
.beta.-hydroxy-dl-aspartic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Although MPTP is not neurotoxic in an enriched granule cell culture, in coculture with cerebellar astrocytes MPTP is toxic to granule cells, presumably because it is converted in astrocytes to MPP+."( The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells.
Kopin, IJ; Marini, AM; Schwartz, JP, 1989
)
0.28
"Destruction of the glutamatergic corticostriatal pathway potentiates the neurotoxic action of 1 mumol L-glutamate injected into the rat striatum, whereas the toxic effects of 10 nmol kainate are markedly attenuated."( Neurotoxicity of L-glutamate and DL-threo-3-hydroxyaspartate in the rat striatum.
McBean, GJ; Roberts, PJ, 1985
)
0.27
" NO also had toxic effects on RGC."( Müller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity.
Barnstable, CJ; Kawasaki, A; Otori, Y, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve of glutamate was shifted by adding DL-TBOA without a significant change in the maximum current."( DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.
Lebrun, B; Nakajima, T; Sakaitani, M; Shigeri, Y; Shimamoto, K; Yasuda-Kamatani, Y; Yumoto, N, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
hydroxy-amino acidA non-proteinogenic alpha-amino acid bearing one or more hydroxy groups at unspecified positions.
amino dicarboxylic acid
C4-dicarboxylic acidAny dicarboxylic acid that contains four carbon atoms.
aspartic acid derivativeAn amino acid derivative resulting from reaction of aspartic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen of aspartic acid by a heteroatom. The definition normally excludes peptides containing aspartic acid residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (149)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (18.12)18.7374
1990's49 (32.89)18.2507
2000's52 (34.90)29.6817
2010's19 (12.75)24.3611
2020's2 (1.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.47 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (3.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other152 (96.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]